Poster Session 1: Donor Factors and Allocation
2014; Lippincott Williams & Wilkins; Volume: 60; Linguagem: Inglês
10.1002/hep.27497
ISSN1527-3350
AutoresBerna Gürsel, Fulya Günşar, Funda Yılmaz, Zeki Karasu, Galip Ersöz, Janske Reiling, David Lockwood, Andrew H. Simpson, Catherine Campbell, Kim R. Bridle, Nishreen Santrampur- Wala, Laurence Britton, Dorothy H. Crawford, Cornelis H.C. Dejong, Jonathan Fawcett, Kilian Friedrich, Christian Rupp, Andreas Wannhoff, Wolfgang Stremmel, Daniel Gotthardt,
Tópico(s)Pharmacological Effects and Toxicity Studies
Resumoerbations during prednisone tapering.The patients with >3 exacerbations were younger than those with <3 exacerbations (56,6+16 vs 37+15, p:0,02).ALT normalized within 6 months in 16 (69,6%) TD patients and in 46 (88,5%) GR patients (p<0,046).Maintenance dose of prednisolon was higher in TD patients (8,05±4,8 vs 4,98±2,2 mg/day; p. 0,016) as expected.Duration of prednisone treatment was longer in TD patients (44±29 vs 27±22 months; p:0,013).Side effects (29% vs 8,3%) and dose reductions (43% vs 20%) of azathioprine were more common in TD patients (p<0,05).ALT, AST, GGT, globulin levels were higher in TD patients comparing to GR patients at 6th month of therapy (p<0,05).Anti smooth muscle antibody (ASMA) positivity was more common in TD patients with higher number of exacerbations (%80 vs %27,8; p:0,056).Liver disease progression was observed in 9 TD (36%) patients and in 8 (14%) GR patients during a median of 27 (6-168) months of follow up (p:0.027).Conclusions.Treatment dependent patients use higher dose of prednisolon with longer duration.Their biochemical remission is achieved later comparing to GR patients'.Azathioprine side effects or intolerance are important issues for treatment dependency.As TD patients have more progressive liver disease, other immmunosupresive drugs such as mycophenolate mofetil or cyclosporine should be tried.
Referência(s)